natgillin/translations-raw huggingface dataset:
In the post-marketing setting, cases of leukaemia have been reported in patients treated with TNF-antagonists. 
V obdobju trženja so pri bolnikih, zdravljenih z antagonisti TNF, poročali o primerih levkemije.
In part 2, 6 of 25 (24%) patients remaining on etanercept experienced a disease flare compared to 20 of 26 (77%) patients receiving placebo (p = 0.007). 
V drugem delu je 6 od 25 (24 %) bolnikov, ki so ostali na etanerceptu, doživelo ponoven izbruh bolezni, v primerjavi z 20 od 26 (77 %) bolnikov, ki so v drugem delu prejemali placebo
Your doctor may decide to continue to monitor you or the child for the presence of infections after you or the child stop using Erelzi. 
Vaš zdravnik se bo morda odločil, da bo vas ali vašega otroka tudi po koncu zdravljenja z zdravilom Erelzi spremljal glede prisotnosti okužb.
Reports of various malignancies (including breast and lung carcinoma and lymphoma) have also been received in the post-marketing period (see section 4.4). 
O različnih malignih obolenjih (vključno z rakom dojke in pljuč ter limfomi) so poročali tudi v obdobju trženja zdravila (glejte poglavje 4.4).
Etanercept is a competitive inhibitor of TNF binding to its cell surface receptors, and thereby inhibits the biological activity of TNF. 
Etanercept je kompetitivni zaviralec vezave TNF na receptorje na površini celice in torej zavira biološko aktivnost
Erelzi should not normally be used in children with polyarthritis or extended oligoarthritis below the age of 2 years or weighing less than 62.5 kg, or in children with enthesitis-related arthritis or psoriatic arthritis below the age of 12 years or weighing less than 62.5 kg, or in children with psoriasis below the age of 6 years or weighing less than 62.5 kg. 
Pri otrocih s poliartritisom ali z razširjenim oligoartritisom, mlajših od 2 let ali ki tehtajo manj kot 62,5 kg, otrocih z artritisom, povezanim z entezitisom, ali s psoriatičnim artritisom, mlajših od 12 let ali ki tehtajo manj kot 62,5 kg, in otrocih s psoriazo, mlajših od 6 let ali ki tehtajo manj kot 62,5 kg, se zdravila Erelzi običajno ne sme uporabljati.
• Signs of cancers: cancers may affect any part of the body including the skin and blood, and possible signs will depend on the type and location of the cancer. 
Rak lahko prizadene katerikoli del telesa, vključno s kožo in krvjo.
EU/1/17/1195/012 12 pre-filled SensoReady pens 
EU/1/17/1195/012 12 napolnjenih injekcijskih peresnikov SensoReady
Do not use this medicine if the seal of the blister is broken, as it may not be safe for you to use. 
Če sta zunanja škatla ali pretisni omot odprta, ne uporabljajte tega zdravila, saj morda ni varno za uporabo.
Infection (including upper respiratory tract infection, bronchitis, cystitis, skin infection)* 
(vključno z okužbo zgornjih dihal, bronhitisom, cistitisom in okužbo kože)*
In this configuration the needle guard is ACTIVATEDDO NOT USE the pre-filled syringe 
V tej konfiguraciji je zapiralo igle AKTIVIRANO - NE UPORABLJAJTE napolnjene injekcijske brizge
Do not use if the syringe is broken or the needle guard is activated. 
Prav tako zdravila ne uporabljajte, če je injekcijska brizga poškodovana ali če je zapiralo igle aktivirano.
• Allergic reactions: If you or the child experience allergic reactions such as chest tightness, wheezing, dizziness or rash, do not inject more Erelzi, and contact your doctor immediately. 
• Alergijske reakcije: Če se pri vas ali otroku pojavijo alergijske reakcije, na primer tiščanje v prsnem košu, piskajoče dihanje, omotica ali izpuščaj, prenehajte injicirati zdravilo Erelzi in nemudoma obvestite zdravnika.
There have been reports of inflammatory bowel disease and uveitis in JIA patients being treated with etanercept from post-marketing sources, including a very small number of cases indicating a positive rechallenge (see section 4.4). 
Viri iz obdobja trženja so poročali o vnetni črevesni bolezni in uveitisu pri bolnikih z JIA, ki so se zdravili z etanerceptom, vključno z zelo majhnim številom primerov, ki kažejo na ponoven pojav bolezni ob naslednjem dajanju zdravila (glejte poglavje 4.4).
• Additional risk minimisation measures 
• Dodatni ukrepi za zmanjševanje tveganj Opozorilna kartica za bolnika
• Severe psoriasis in patients from the age of 6 years and weighing 62.5 kg or more who have had an inadequate response to (or are unable to take) phototherapies or other systemic therapies. 
• za zdravljenje hude psoriaze pri bolnikih, starejših od 6 let, ki tehtajo 62,5 kg ali več, ki so se nezadostno odzvali na fototerapije ali druge sistemske terapije (ali jih niso prenašali).
Pairwise comparison p-values: * = p < 0.05 for comparisons of etanercept vs. methotrexate, † = p < 0.05 for comparisons of etanercept + methotrexate vs. methotrexate and ϕ = p < 0.05 for comparisons of etanercept + methotrexate vs. etanercept. 
Vrednosti p za primerjavo po parih: * = p < 0,05 za primerjavo etanercepta z metotreksatom, † = p < 0,05 za primerjavo kombinacije etanercept + metotreksat z metotreksatom in φ = p < 0,05 za primerjavo kombinacije etanercept + metotreksat z etanerceptom.
After the medicine has been injected, the needle guard will be activated to cover the needle. 
Po injiciranju zdravila se zapiralo igle aktivira in pokrije iglo.
L-Lysine hydrochloride Sodium hydroxide (for pH adjustment) Hydrochloric acid (for pH adjustment) Water for injections 
L-lizinijev klorid natrijev hidroksid (za uravnavanje pH-vrednosti) solna kislina (za uravnavanje pH-vrednosti) voda za injekcije
What you need to know before you use Erelzi 
Kaj morate vedeti, preden boste uporabili zdravilo Erelzi Ne uporabljajte zdravila Erelzi
Do not use this medicine after the expiry date which is stated on the carton and the label of the pre-filled syringe after EXP. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in nalepki napolnjene injekcijske brizge poleg oznake »EXP«.
Erelzi may be stored outside of the refrigerator at temperatures up to a maximum of 25 °C for a single period of up to four weeks; after which, it should not be refrigerated again. 
Pred pripravo raztopine zdravila Erelzi lahko zdravilo Erelzi shranjujete izven hladilnika pri temperaturi do največ 25 °C za enkratno obdobje do štirih tednov, po katerem se ga ne sme več ohladiti.
39.8% †, ϕ 
22,0 % 39,8 % †,φ
Erelzi contains sodium 
Zdravilo Erelzi vsebuje natrij
In another open-label single-arm study, 60 patients with extended oligoarthritis (15 patients aged 2 to 4, 23 patients aged 5 to 11 and 22 patients aged 12 to 17 years old), 38 patients with enthesitis-related arthritis (12 to 17 years old), and 29 patients with psoriatic arthritis (12 to 17 years old) were treated with etanercept at a dose of 0.8 mg/kg (up to a maximum of 50 mg per dose) administered weekly for 12 weeks. 
V drugi odprti študiji z eno skupino se je z etanerceptom v odmerku 0,8 mg/kg (do največ 50 mg na odmerek) enkrat na teden zdravilo 60 bolnikov z razširjenim oligoartritisom (15 bolnikov, starih od 2 do 4 leta, 23 bolnikov, starih od 5 do 11 let, in 22 bolnikov, starih od 12 do 17 let), 38 bolnikov z artritisom, povezanim z entezitisom (starih od 12 do 17 let) in 29 bolnikov s psoriatičnim artritisom (starih od 12 do 17 let).
Thus, it is not possible to administer Erelzi to paediatric patients that require less than a full 25 mg or 50 mg dose. 
Zato zdravila Erelzi ni mogoče dati pediatričnim bolnikom, ki potrebujejo odmerek manj kot polnih 25 mg ali 50 mg. Pediatrični bolniki, ki potrebujejo odmerek, drugačen kot polnih 25 mg ali 50 mg, ne smejo dobiti zdravila Erelzi.
Do not use the syringe after the expiry date which is stated on the outer box or syringe label after “EXP”. 
Injekcijske brizge ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na zunanji škatli in na nalepki injekcijske brizge poleg oznake "EXP".
Treatment of adults with moderate to severe plaque psoriasis who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy, including ciclosporin, methotrexate or psoralen and ultraviolet-A light (PUVA) (see section 5.1). 
Zdravljenje zmerne do hude psoriaze v plakih pri odraslih, ki se ne odzovejo na drugo sistemsko zdravljenje, vključno s ciklosporinom, metotreksatom ali psoralenom in ultravijolično svetlobo UV-A
• if you or the child have, or are at risk of developing a serious blood infection called sepsis. 
• če imate vi ali otrok resno okužbo krvi (sepso) ali če pri vas ali otroku obstaja tveganje za njen pojav.
Erelzi is supplied as a solution for injection in a pre-filled pen (SensoReady). 
Zdravilo Erelzi je na voljo kot raztopina za injiciranje v napolnjenem injekcijskem peresniku (SensoReady).
This medicinal product contains less than 1 mmol sodium (23 mg) per 50 mg, that is to say essentially ‘sodium-free'. 
To zdravilo vsebuje manj kot 1 mmol (23 mg) natrija na 50 mg, kar v bistvu pomeni ‘brez natrija'.
There have been reports of hypoglycaemia following initiation of etanercept in patients receiving medicinal product for diabetes, necessitating a reduction in anti-diabetic medicinal products in some of these patients. 
poročali o hipoglikemiji, zaradi katere je bilo treba pri nekaterih od teh bolnikov zmanjšati odmerek zdravila za zdravljenje sladkorne bolezni.
63.2% †, ϕ 
43,0 % 63,2 % †,φ
Physicians should exercise caution when considering the use of Erelzi in patients with a history of recurring or chronic infections or with underlying conditions that may predispose patients to infections, such as advanced or poorly controlled diabetes. 
Zdravniki morajo biti previdni, kadar se odločajo za zdravljenje z zdravilom Erelzi pri bolnikih s ponavljajočimi se ali kroničnimi okužbami v anamnezi ali z drugimi osnovnimi stanji (kot je na primer napredovala ali neurejena sladkorna bolezen), ki bi lahko povečala dovzetnost bolnikov za okužbe.
With twice-weekly doses, it is anticipated that steady-state concentrations are approximately twice as high as those observed after single doses. 
Pričakovati je, da bodo koncentracije v stanju dinamičnega ravnovesja po odmerjanju 2-krat tedensko približno dvakrat večje od tistih, izmerjenih po enkratnem odmerku.
Instructions for use and handling of the Erelzi pre-filled syringe Before injection, Erelzi single-use pre-filled syringe should be allowed to reach room temperature (approximately 15 to 30 minutes). 
Navodila za uporabo in ravnanje z zdravilom Erelzi napolnjena injekcijska brizga Pred injiciranjem je treba napolnjeno injekcijsko brizgo zdravila Erelzi za enkratno uporabo segreti na sobno temperaturo (počakati približno 15 do 30 minut).
Key elements of the Erelzi Patient Alert Card 
Ključne sestavine opozorilne kartice za bolnika
This medicinal product contains less than 1 mmol sodium (23 mg) per 25 mg or 50 mg, that is to say essentially ‘sodium-free'. 
To zdravilo vsebuje manj kot 1 mmol (23 mg) natrija na 25 mg ali 50 mg, kar v bistvu pomeni ‘brez natrija'.
The syringe inside the pen is made from clear type I glass with a stainless steel 27 gauge ½ inch needle and an inner rubber needle cap, containing 1.0 ml of solution. 
Brizga v peresniku je narejena iz prozornega stekla tipa I z iglo iz nerjavečega jekla velikosti 27 G, ½ palca, in notranjim gumijastim pokrovčkom igle, ter vsebuje 1,0 ml raztopine.
Pairwise comparison p-values: † = p < 0.05 for comparisons of etanercept + methotrexate vs. methotrexate and ϕ = p < 0.05 for comparisons of etanercept + methotrexate vs. etanercept. 
Vrednosti p za primerjavo po parih: † = p < 0,05 za primerjavo kombinacije etanercept + metotreksat z metotreksatom in φ = p < 0,05 za primerjavo kombinacije etanercept + metotreksat z etanerceptom.
One hundred and twelve (112) patients were randomised to receive a dose of 25 mg of etanercept (n = 57) or placebo (n = 55) twice a week for 24 weeks. 
Randomizirali so sto dvanajst (112) bolnikov, ki so 24 tednov dvakrat na teden dobivali25 mg odmerek etanercepta (n = 57) ali placebo (n = 55).
4 pre-filled SensoReady pens. 
4 napolnjeni injekcijski peresniki SensoReady.
The possibility exists for TNF-antagonists, including Erelzi, to affect host defences against infections and malignancies since TNF mediates inflammation and modulates cellular immune responses. 
Za antagoniste TNF, vključno z zdravilom Erelzi, velja, da lahko vplivajo na naravno odpornost bolnika proti okužbam in malignim obolenjem, saj TNF sodeluje pri vnetju in uravnava celični imunski odziv.
Before your injection: 
Pred injiciranjem:
A higher rate of major birth defects was observed in one observational study comparing pregnancies exposed to etanercept (n = 370) during the first trimester with pregnancies not exposed to etanercept or other TNF-antagonists (n = 164) (adjusted odds ratio 2.4, 95% CI: 1.0 - 5.5). 
V 1 opazovalni študiji, kjer so primerjali nosečnosti, izpostavljene etanerceptu (n = 370) v prvem trimesečju, z nosečnostmi, ki niso bile izpostavljene etanerceptu ali drugim antagonistom TNF (n = 164), so opazili večji delež resnih prirojenih napak (prilagojeno razmerje obetov 2,4, 95 % IZ: 1,0-5,5).
Not included in the carton: 
Pripomočki, ki niso priloženi:
Clinical efficacy results at 12 months: comparison of etanercept vs. methotrexate vs. etanercept in combination with methotrexate in patients with RA of 6 months to 20 years duration 
Rezultati klinične učinkovitosti po 12 mesecih: primerjava med etanerceptom, metotreksatom in kombinacijo etanercepta in metotreksata pri bolnikih z RA, ki je trajal 6 mesecev do 20 let
• A needle-free AI device for demonstration will be available for patient practice use. 
• bolnikom bo za vajo na voljo predstavitveni avtoinjektor brez igle.
• The pen can now be removed. 
• Zdaj lahko injekcijski peresnik odstranite s kože.
Clear type I glass syringe with a stainless steel 27 gauge ½ inch needle with a needle guard with finger flange, rubber needle cap and plastic plunger, containing 0.5 ml or 1.0 ml of solution. 
Zdravilo Erelzi raztopina za injiciranje v napolnjeni injekcijski brizgi Injekcijska brizga iz prozornega stekla tipa I z iglo iz nerjavečega jekla velikosti 27 G, ½ palca, z zapiralom igle in držalom za prste, gumijastim pokrovčkom igle in plastičnim batom, ki vsebuje 0,5 ml ali 1,0 ml raztopine.
Serious infections (including pneumonia, cellulitis, arthritis bacterial, sepsis and parasitic infection)* 
celulitisom, bakterijskim artritisom, sepso in parazitsko okužbo)*
37% †, ϕ 
18 % 37 %†,φ
• Anti-diabetic medicines: Tell your doctor if you or the child have diabetes or are taking medicines to treat diabetes. 
• Zdravila za zdravljenje sladkorne bolezni: Povejte zdravniku, če imate vi ali otrok sladkorno bolezen ali če kateri od vaju jemlje zdravila za zdravljenje sladkorne bolezni.
However, limited safety data from a patient registry suggest that the safety profile in children from 2 to 3 years of age is similar to that seen in adults and children aged 4 years and older, when dosed every week with 0.8 mg/kg subcutaneously (see section 5.1). 
Vendar pa omejeni podatki o varnosti iz registra bolnikov nakazujejo, da je pri subkutani uporabi zdravila v odmerku 0,8 mg/kg enkrat na teden pri otrocih, starih od 2 do 3 let, varnostni profil podoben profilu pri odraslih in otrocih,
Do not remove the needle cap until just before you give the injection. 
Pokrovček igle snemite šele tik pred injiciranjem.
The primary measure of efficacy (ASAS 40) was a 40% improvement in at least three of the four ASAS domains and absence of deterioration in the remaining domain. 
Primarno merilo za učinkovitost (ASAS 40) je bilo 40 % izboljšanje vsaj treh od štirih domen ASAS
Instructions for use and handling of the Erelzi pre-filled SensoReady pen Before injection, Erelzi single-use pre-filled pens should be allowed to reach room temperature (approximately 15 to 30 minutes). 
Navodila za uporabo in ravnanje z zdravilom Erelzi SensoReady napolnjen injekcijski peresnik Pred injiciranjem je treba napolnjen injekcijski peresnik zdravila Erelzi za enkratno uporabo segreti na sobno temperaturo (počakati približno 15 do 30 minut).
In a population pharmacokinetics analysis in ankylosing spondylitis patients, the etanercept steady state AUCs were 466 µg•hr/ml and 474 µg•hr/ml for 50 mg etanercept once weekly (N = 154) and 25 mg twice weekly (N = 148), respectively. 
Pri analizi populacijske farmakokinetike pri bolnikih z ankilozirajočim spondilitisom so vrednosti AUC etanercepta v stanju dinamičnega ravnovesja pri uporabi etanercepta v odmerku 50 mg enkrat na teden (n = 154) znašale 466 μg·h/ml, pri uporabi etanercepta v odmerku 25 mg dvakrat na teden (n = 148) pa 474 μg·h/ml.
Serious allergic/ anaphylactic reactions (including angioedema, bronchospasm), sarcoidosis 
anafilaktične reakcije (vključno z angioedemom in bronhospazmom), sarkoidoza poslabšanje simptomov dermatomiozitisa
In post-marketing experience, approximately half of all of the case reports of opportunistic infections worldwide were invasive fungal infections. 
opisanih v poročilih o primerih oportunističnih okužb po vsem svetu, invazivnih glivičnih okužb.
If a caregiver is giving you the injection, the outer upper arms may also be used. 
Če vam injekcijo daje negovalec, lahko zdravilo injicira tudi na zunanji strani nadlakti.
Patients weighing 62.5 kg or more may be dosed using a fixed-dose pre-filled syringe or pre-filled pen. 
Bolnikom, ki tehtajo 62,5 kg ali več, lahko dajemo odmerke zdravila z napolnjeno injekcijsko brizgo ali napolnjenim injekcijskim peresnikom s stalnim odmerkom.
Adult patients treated with etanercept and anakinra were observed to have a higher rate of serious infection when compared with patients treated with either etanercept or anakinra alone (historical data). 
Sočasno zdravljenje z anakinro Pri odraslih bolnikih, zdravljenih z etanerceptom in anakinro, so opazili večjo stopnjo resnih okužb kot pri bolnikih, zdravljenih samo z etanerceptom ali samo z anakinro (retrospektivni podatki).
All patients and parents/caregivers should be advised that if the patient develops signs and symptoms suggestive of blood dyscrasias or infections (e.g., persistent fever, sore throat, bruising, bleeding, paleness) whilst on Erelzi, they should seek immediate medical advice. 
Vse bolnike in starše/skrbnike je treba opozoriti, da morajo pri bolniku v primeru pojava znakov ali simptomov, ki kažejo na krvno diskrazijo ali okužbo (npr. dolgotrajna zvišana telesna temperatura, vnetje žrela, podplutbe, krvavitve,
Patients were between 18 and 70 years of age and had active psoriatic arthritis (≥ 3 swollen joints and ≥ 3 tender joints) in at least one of the following forms: (1) distal interphalangeal (DIP) involvement; (2) polyarticular arthritis (absence of rheumatoid nodules and presence of psoriasis); (3) arthritis mutilans; (4) asymmetric psoriatic arthritis; or (5) spondylitis-like ankylosis. 
(1) distalna interfalangealna prizadetost (DIP); (2) poliartikularni artritis (odsotnost revmatoidnih nodulov in prisotnost psoriaze); (3) artritis mutilans; (4) asimetrični psoriatični artritis ali (5) spondilitisu podobna ankiloza.
Erelzi is only available as 25 mg pre-filled syringe and 50 mg pre-filled syringe and pre-filled pen. 
Zdravilo Erelzi je na voljo samo kot 25 mg napolnjena injekcijska brizga in 50 mg napolnjena injekcijska brizga in napolnjen injekcijski peresnik.
Your doctor will determine if Erelzi is an appropriate treatment. 
Zdravnik bo presodil o primernosti zdravljenja z zdravilom Erelzi.
This may include a thorough medical history, a chest X-ray and a tuberculin test. 
rentgenskim slikanjem prsnega koša in tuberkulinskim testom.
You may also use the lower abdomen, but not the area 5 centimetres around the navel (belly button). 
Zdravilo lahko injicirate tudi na spodnjem delu trebuha, vendar ne v predelu, oddaljenem 5 centimetrov ali manj od popka.
• This means the medicine has been delivered. 
• To pomeni, da je odmerek zdravila injiciran v celoti.
Dimeric soluble receptors, such as etanercept, possess a higher affinity for TNF than monomeric receptors and are considerably more potent competitive inhibitors of TNF binding to its cellular receptors. 
imajo večjo afiniteto za TNF kot monomerni receptorji in so veliko bolj učinkoviti kompetitivni zaviralci vezave TNF na celične receptorje.
• Choose a different site each time you give yourself an injection. 
• Vsakokrat, ko si injicirate zdravilo, izberite drugo mesto na koži.
• For enthesitis-related arthritis in patients from the age of 12 years and weighing 62.5 kg or more when other widely used treatments have not worked well enough or are not suitable for them. 
• za zdravljenje artritisa, povezanega z entezitisom, pri bolnikih, starejših od 12 let, ki tehtajo 62,5 kg ali več, če zdravljenje z običajnimi oblikami zdravljenja ni bilo uspešno ali jih bolniki niso prenašali.
There have been post-marketing reports of worsening of CHF, with and without identifiable precipitating factors, in patients taking etanercept. 
Obstajajo poročila iz obdobja trženja o poslabšanju KSP pri bolnikih, ki jemljejo etanercept, ob prisotnosti dejavnikov, ki bi lahko sprožili tako poslabšanje, in brez njih.
Malignancies, some fatal, have been reported among children, adolescents and young adults (up to 22 years of age) treated with TNF-antagonists (initiation of therapy ≤ 18 years of age), including etanercept, in the post-marketing setting. 
Pri otrocih, mladostnikih in mladih odraslih (do 22. leta starosti), ki so se zdravili z antagonisti TNF
Take the blister out of the refrigerator and leave it unopened for about 15-30 minutes so that it reaches room temperature. 
Pretisni omot vzemite iz hladilnika in ga pustite zaprtega približno 15-30 minut, da doseže sobno temperaturo.
Adult patients with non-radiographic axial spondyloarthritis 
Odrasli bolniki z radiografsko nezaznavnim aksialnim spondilartritisom
Contents of the pack and other information Instructions for Use of the Erelzi SensoReady pen 
Vsebina pakiranja in dodatne informacije Navodila za uporabo zdravila Erelzi napolnjen injekcijski peresnik SensoReady
Multipacks contain 12 (3 packs of 4) 25 mg or 50 mg pre-filled syringes or pre-filled pens or 8 (2 packs of 4) or 24 (6 packs of 4) 25 mg pre-filled syringes of Erelzi. 
Skupna pakiranja vsebujejo 12 (3 pakiranja s po 4) 25-mg ali 50-mg napolnjenih injekcijskih brizg ali napolnjenih injekcijskih peresnikov ali 8 (2 pakiranji s po 4) ali 24 (6 pakiranj s po 4) 25-mg napolnjenih injekcijskih brizg z zdravilom Erelzi.
The most commonly reported invasive fungal infections included Candida, Pneumocystis, Aspergillus and Histoplasma. 
Candida, Pneumocystis, Aspergillus in Histoplasma.
Hepatitis B reactivation, listeria 
atipičnimi mikobakterijskimi, virusnimi okužbami in okužbami z reaktivacija hepatitisa B, listerija
Infections and infestations 
Infekcijske in parazitske bolezni okužba
For a more comfortable injection, take the pen out of the refrigerator 15-30 minutes before injecting to allow it to reach room temperature. 
Da bo injiciranje manj neprijetno, vzemite injekcijski peresnik iz hladilnika 15-30 minut pred injiciranjem, da se lahko ogreje na sobno temperaturo.
Mean serum concentration profiles at steady state in treated RA patients were Cmax of 2.4 mg/l vs. 2.6 mg/l, Cmin of 1.2 mg/l vs. 1.4 mg/l, and partial AUC of 297 mg•hr/l vs. 316 mg•hr/l for 50 mg etanercept once weekly (n = 21) vs. 25 mg etanercept twice weekly (n = 16), respectively. 
Pri bolnikih z revmatoidnim artritisom so bile povprečne koncentracije v serumu v stanju dinamičnega ravnovesja naslednje: pri zdravljenju z etanerceptom v odmerku 50 mg enkrat na teden (n = 21) je vrednost Cmax znašala 2,4 mg/l, vrednost Cmin 1,2 mg/l, delna AUC pa 297 mg·h/l, pri zdravljenju z etanerceptom v odmerku 25 mg dvakrat na teden (n = 16) pa je vrednost Cmax znašala 2,6 mg/l, vrednost Cmin 1,4 mg/l, delna AUC pa 316 mg·h/l.
This study also showed no increased risks of minor birth defects, preterm birth, stillbirth, or infections in the first year of life for infants born to women exposed to etanercept during pregnancy. 
prezgodnji porod, mrtvorojenost ali okužbe v prvem letu življenja pri dojenčkih, katerih matere so bile v času nosečnosti izpostavljene etanerceptu.